Main Newsletter
Mastery Series
Therapy Series
 

Letter From The Editor

Letter from the Editor, #687: Sickle Cell and Diabetes

Last Monday, I was seeing patients at an endocrinologist's office and he asked us if we could see one more patient before we left. This patient was a 38 y/o African American female who had had diabetes for 3 years. Her last A1c was 6.2 but her...


Special Edition, SGLT2-Inhibitors, Editor's Desk

We have now had about three months of use of the new medication, Invokana (canagliflozin). During this time many publications including our own newsletter have been running feature stories as well as ads for the product. This delivery of...


Editor's Note, DCMS #146: New Homerun Slides on the Obesity Diabetes Epidemic

Stan Schwartz, MD, FACP, FACE has been doing clinical work for the University of Pennsylvania for many years. He has also worked with many obese patients as Director of the Obesity Program at the Cardiometabolic Diabetes Center. This week, after...



Letter from the Editor, #686: How Pharmacists Can Help with Medication Adherence

There have been a lot of additions to the diabetes drug armada over the past year and we have spent a lot of time helping you learn how best to use them. But over and over we have seen that no matter how good the drugs are, they just won't help if...


Editor's Note, DCMS #145:

If you look at the notes from the AACE conference, the AAFP conference and the recent ADA Scientific Sessions, you'll notice a lot of new algorithms for the treatment of diabetes. All this information reminds me of when I was working on improving...


Letter from the Editor, #685: Autonomic Neuropathy and Exercise

Autonomic neuropathy is damage to the central nervous system that is often caused by diabetes and can result in silent ischemia, hyperthermia, or lightheadedness with standing and during exercise. These factors make recommending physical activity...


Editor's Note, DCMS #144: Treating Calluses in Diabetic Patients

Often times when we see a diabetes patient, the first thing we look for are problems with the feet. When I meet a new patient, I always ask whether they have seen a podiatrist. These physicians specialize in problems from the tips of the toes to...


Letter from the Editor #684

Last week I wrote about a pharmacist colleague who contacted me about using long acting insulin on a prn basis. Our discussion led to the idea of starting insulin at diagnosis. Some of you commented positively on using...


Editor's Note, DCMS #143:

We often emphasize food choices for our diabetes patients and one overriding target is to decrease carbohydrates. Although this makes great sense in an overweight type 2 patient on orals, or orals and insulin, it is not necessarily as important in...


Letter from the Editor, #683: Insulin as Needed

A colleague, the director of pharmacy for a large multi-office ACO in our area, called me recently. One of his Clinical MTM pharmacists had heard from some patients who were using Lantus or Levemir as needed. He contacted me to find out if I...


Editor's Note, SGLT2-I Special Edition Issue #3

Steve, Andrew and I are back from the 73rd ADA Scientific Sessions in Chicago with lots of great information for you including many studies on current medications either showing improved outcomes or the value of using existing medications in new...


Editor's Desk, DCMS #142: DKA in Children and Adolescents

Diabetic ketoacidosis (DKA) is the leading cause of morbidity and mortality in children with type 1 diabetes mellitus and the emergency room is where the these kids usually end up. The onset of DKA can occur at anytime and can occur in children who...


Letter from the Editor #682:

This weekend finds all of us at the ADA meeting in Chicago and we have some early releases on some of the findings. The great thing about the Scientific Sessions is that researchers of new drugs, techniques and methods of diabetes care put all...


Editor's Desk, DCMS #141

We are moving closer to the full bore effect of the Affordable Care Act and although there are many opinions as to how good or bad the idea is, it has increased healthcare coverage for many Americans. Part of the program's positive ideas includes...


Letter from the Editor #681

This week I was talking to a group of physician interns about food choices for diabetes and was trying to explain the value of a low carbohydrate program. During the discussion one of the students interrupted to advise the group that eating less...


Editor's Desk, DCMS #140

I just finished a class this morning with seven patients in an endocrinologist's office. They were seven of the most diverse patients I have ever had in a class; two patients on orals, an oral and basal insulin patient, a type 2 who was dependent...


Letter from the Editor, #680: Upsides and Downsides of ACO's

We have brought you a lot of information on the emergence of Accountable Care Organizations (ACOs) as a new model...


Editor's Note, DCMS #139

Jeremy Hodson Pettus, MD, and Steven Edelman, MD are back this week to help you understand adjunctive therapies that you can use with insulin patients to improve control of A1c's, while improving weight loss success.


Letter from the Editor #679: Sheri Colberg's New Book

Sheri R. Colberg, PhD, FACSM has been writing for us for the past seven years and she is our go-to guru when it comes to anything that has to do with diabetes and physical activity. We are proud to announce that her new...


Editor's Note, DCMS #138

This week in our Homerun Slides we get back to working with medications to focus on the core defects of diabetes and how selecting the right...


Letter from the Editor #678

We are at a point with oral medications for diabetes where there are new drug approvals in recently approved classes, new drug classes where the first in class is approved, as well as late trial research moving quickly for...


Editor's Note, DCMS #137

I just finished up a two day advisory board meeting for an insulin manufacturer. We looked at some new products and studies as well as new ideas about diabetes care. Part of our discussion had to do with the increased use of EMRs (electronic...


Letter from the Editor, #677

This week I happened to run into a physician friend I had not seen for a while. While we were chatting, I noticed that he must have gotten at least six pages from his answering service. Each time he had to call in and listen to the operator...


Letter from the Editor, SGLT-2 Inhibitors, Special Edition #2

Last month, in our first issue of these special edition newsletters we gave you the tools to become an expert on SGLT2-I therapy. In our second edition we want to...


Editor's Desk, DCMS #136

We often talk about the value of controlling lipids and glucose and their relation to patient health. If patients would only do what we tell them then the results would be good and our jobs would be easier. With the recent changes in healthcare,...


Letter from the Editor #676

This past week we had our PharmD candidate, Lauren Self, scour the information from the AACE meeting in Phoenix, in order to prepare the best articles for you to review. The new AACE guidelines that Dr. Alan...


DCMS #135

Have you ever heard of 1,5-Anhydroglucitol (1,5-AG)? If not get ready to learn in this week's Homerun Slides why testing for this compound will give...


Letter from the Editor, #675

Things are in full swing at AACE this weekend and we will be bringing you the most important and usable information in next week's newsletter.    One of the most talked-about insulin-delivery products is the


DCMS #134

Last week in our Homerun Slides we started to talk about quality measures in patient care. Whenever we get information about this concept it always revolves around the practitioner, and how good a job we do, but often patient care is...


Letter from the Editor, #674

This week there is a new report out on the increased spending per year for diabetes care. This number is now well over 240 billion dollars, and when you add...


Editor's Note, DCMS #133

There is a lot of clamor about the new way of providing healthcare, and how quality becomes important to maximize reimbursement potential. A part of this quality initiative involves Value Based Purchasing. To help you understand the concept of VBP...


Letter from the Editor #673

If you have been a little behind on reading your emails you might not yet have seen the special edition that we sent out on the new SGLT2-Inhibitors now that the...


Editor's Note, DCMS #132

This week we continue our Clinical Text focus on macrovascular disease associated with diabetes. Dr. Beaser gets into a discussion as to which...


Letter from the Editor #672

This past week I was in the DC area talking to physicians about patient-centered Medical Homes and Accountable Care Organizations (ACO's). Much of the conversation revolved around Medicare and Medicaid plans and patients. As we were talking about...


Special Edition SGLT2 Letter from the Editor, Issue 1

This week we are pleased to bring you a special edition on the new SGLT2 Inhibitors. While many other publications have had information on this new class and the first of its kind approved drug, we decided to go into much more depth in our delivery...


Editor's Note, DCMS #131

Over the last seven weeks over 50% of the Diabetes Disasters Averted we have presented to you revolved around insulin errors. Our typical incident involves a medical professional finding an error just before it does severe harm to a patient....


Letter from the Editor #671

Our newly diagnosed patients receive so much information from friends, family, and the internet that they become desensitized to having diabetes and what that means in real terms. This overload of information and long list of do's and don'ts can be...


Editor's Note, DCMS #130

About three quarters of our diabetes patients have dyslipidemia and elevated triglycerides, along with high insulin resistance and an increased risk of CAD. Our Clinical Text from Joslin


Letter from the Editor #670

Last November our intern Andre McMahon put together a good article on How the Liver...


Editor's Note, DCMS #129

One of the most often mentioned and least understood acronyms in diabetes is HOMA. We see this four letter abbreviation used in almost every diabetes study and evaluation but exactly what is HOMA...



Navigate through our listing of Letter From The Editor articles here.
First Previous Next Last

593 Total articles for Letter From The Editor


Browse our other news categories below.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Looking for a particular Newsletter Issue? Click Here


Cast Your Vote
Will you prescribe inhaled insulin (Afrezza) when it becomes available this year?
CME/CE of the Week
Christine A. Kessler, RN, MN, CSANP

Category: Nutrition
Credits: .75



Advertisement


Search Articles On Diabetes In Control